
JPH203
CAS No. 1037592-40-7
JPH203( KYT-0353 | KYT0353 | KYT 0353 | JPH-203 )
Catalog No. M10188 CAS No. 1037592-40-7
JPH203 (KYT-0353)?is a potent, selective L-type amino acid transporter 1 (LAT1, SLC7A5) inhibitor with IC50 of 60 nM (leucine uptake inhibition).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 53 | In Stock |
![]() ![]() |
5MG | 76 | In Stock |
![]() ![]() |
10MG | 109 | In Stock |
![]() ![]() |
25MG | 182 | In Stock |
![]() ![]() |
50MG | 327 | In Stock |
![]() ![]() |
100MG | 420 | In Stock |
![]() ![]() |
200MG | 620 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameJPH203
-
NoteResearch use only, not for human use.
-
Brief DescriptionJPH203 (KYT-0353)?is a potent, selective L-type amino acid transporter 1 (LAT1, SLC7A5) inhibitor with IC50 of 60 nM (leucine uptake inhibition).
-
DescriptionJPH203 (KYT-0353)?is a potent, selective L-type amino acid transporter 1 (LAT1, SLC7A5) inhibitor with IC50 of 60 nM (leucine uptake inhibition), but not LAT2; inhibits cell growth in HT-29 cells with IC50 of 4.1 uM, also inhibits (14)C-leucine uptake in mouse renal proximal tubule cells expressing LAT1 and inhibits cell growth with IC50 of 0.14 and 16.4 uM, respectively; significant inhibits HT-29 tumor growth in vivo.Solid Tumors Phase 1 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsKYT-0353 | KYT0353 | KYT 0353 | JPH-203
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research AreaCancer
-
IndicationSolid Tumors
Chemical Information
-
CAS Number1037592-40-7
-
Formula Weight472.32066
-
Molecular FormulaC23H19Cl2N3O4
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESC1=CC=C(C=C1)C2=NC3=CC(=CC(=C3O2)COC4=C(C=C(C=C4Cl)CC(C(=O)O)N)Cl)N
-
Chemical NameL-Tyrosine, O-[(5-amino-2-phenyl-7-benzoxazolyl)methyl]-3,5-dichloro-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Oda K, et al. Cancer Sci. 2010 Jan;101(1):173-9.
2. Yun DW, et al. J Pharmacol Sci. 2014;124(2):208-17.
3. Wempe MF, et al. Drug Metab Pharmacokinet. 2012;27(1):155-61.
4. Rosilio C, et al. Leukemia. 2015 Jun;29(6):1253-66.
molnova catalog



related products
-
Pamrevlumab
Pamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
-
AGN 192870
AGN 192870 is a potent retinoic acid receptor (RAR) antagonist.AGN 192870 can be used to study cell growth arrest, differentiation and apoptosis.
-
HNPMI
HNPMI is an EGFR inhibitor that induces G0/G1 phase arrest of CRC cells in colorectal cancer, regulates enzymes associated with apoptosis, and can promote apoptosis, and can be used for the study of colorectal cancer.